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21st Century Developments in the Understanding and Control of 
Molecular Solids 
Jonathan W. Steeda*
The first decades of the 21st Century have seen very significant 
advances in the understanding, prediction and control of 
molecular solids. Advances in crystallization techniques, 
polymorphism, co-crystals, co-amorphous materials, crystal 
engineering and instrumentation have all contributed to what is 
now an extremely active field. There are huge fundamental 
implications as well as applications particularly in the 
pharmaceutical, agrochemicals and energetic materials sectors. 
This highlight article surveys some of the key recent 
developments. 
Crystals have always fascinated both scientists and artists 
alike. Their symmetry and clean geometric shapes seem to 
arise like magic from the Earth. As early as 1657 Scotsman, 
William Davidson (called ‘Davissone’) noted the regular 
Platonic shapes in crystalline solids and natural forms, and 
began the field of crystallography: “a new subject which, so far 
as I know, none before me has elaborated”, Fig. 1. Fast 
forward to 1832 when keen visual observation of different 
crystal shapes allowed Friedrich Wöhler and Justus von Liebig 
to describe the first incidence of polymorphism in a molecular 
crystal; different crystal packing arrangements of the molecule 
benzamide.1 While Davissone, Wöhler and von Liebig 
recognised that there was something special about these 
remarkable, self-assembled materials it was not until the 
advent of X-ray diffraction in the early 20th century that it 
became possible to study their internal structure and begin to 
understand how and why crystals form in the way they do. 
Work in the 1960s by microscopist Walter McCrone2 brought 
about a much greater understanding of the diversity of solid 
forms molecules could adopt but even so, chemists remained 
far from being able to control or predict the outcome of the 
crystallization process. As late as 1988 Maddox described the 
ongoing inability to predict crystal structure from molecular 
structure as an “ongoing scandal”.3 Maddox was writing 
around the time I began my own research in molecular 
crystals. Growing single crystals for X-ray analysis was a black 
art, and the rare sample that was big enough to make it down 
to the diffractometer room endured an anxious wait to see if it 
was stable out of the mother liquor, could pass the 
photographic checks and survive long enough at room 
temperature to give a usable data set.  
 
 
Figure 1. The occurrence of regular Platonic shapes in crystalline solids and 
natural forms (from W. Davisonne, Les Elements de la Philosophie de l’Art du Feu, 
ou Chemie, Paris 1657.) 
 
 Against this backdrop of magic and luck, I wanted to 
encapsulate in this short highlight article just how far we have 
come in the last two decades in the understanding, control 
and even prediction of the structure and properties of 
molecular solids. That is not to say, of course, that the field is 
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all sewn up, but rather it is something of an exciting time to be 
looking at crystalline and amorphous materials.  
 A key driver in the solid forms arena is the burgeoning 
interest and funding from the pharmaceutical industry in 
particular, and to a lesser extent the agrochemicals and 
energetic materials sectors. Because molecular solid form 
impacts directly on solid state properties that are of direct 
relevance to drug formulation, the field has seen considerable 
investment and consequent dramatic growth in research 
effort.4-6 In addition, intellectual property considerations have 
been a very significant driver. Triggered in part by the 1984 
Hatch-Waxman act7 allowing rapid access to market of generic 
pharmaceuticals and the subsequent Zantac (ranitidine 
hydrochloride) litigation,8 it is now almost universal to actively 
seek to identify new solid forms. The patent protection offered 
by the Form A crystal patent, for example, was a significant 
driver behind the  $1Bn 2015 acquisition of the US rights to the 
painkiller tapentadol hydrochloride.9 Litigation needs have also 
driven the development of some novel separation approaches 
such as the use of density separation fluids10 or magnetic 
levitation11 to separate polymorphs of APIs from one another 
or from excipients. 
 Perhaps the most obvious shift over the past 20 years has 
been the intense focus on co-crystals and even more recently 
on amorphous and co-amorphous materials as a means to 
enhance drug dissolution and bioavailability.12-14 Fig. 2 
summarizes the position of co-crystals and co-amorphous 
solids within the landscape of molecular materials. The 
classification of crystalline multi-component systems has been 
hotly debated.15 If the components bear formal charges they 
are considered salts. Neutral multi-component systems are 
considered solvates (including hydrates) if one component 
played the role of solvent during the crystallization process. If 
not, the system is a co-crystal or molecular complex. 
Sometimes the artificial distinction of whether a component is 
solid at room temperature has been used to distinguish 
solvates from co-crystals, however this criterion is 
unsatisfactory since it leads to different classification of some 
materials in labs of different temperature. Co-crystals also 
often (although not always) exhibit a well-defined 
stoichiometry and typically possess rather different properties 
to non-stoichiometric inclusion compounds where some sites 
are unoccupied, or one component can be free to move in a 
channel. Multicomponent crystalline solids can also exist as 
solid solutions in which one component is randomly 
distributed in a crystal of another. 
 
Figure 2. The scope of molecular materials (adapted from ref. 16). 
 
Very recently the regulatory status of co-crystals has been 
defined by the US FDA which states “[a] co-crystal with a 
pharmaceutically acceptable coformer … can be considered to 
be a pharmaceutical co-crystal and has a regulatory 
classification similar to that of a polymorph of the API”.17 
There are now a number of FDA approved co-crystal drug 
products including Entresto® (sacubitril-valsartan), Lexapro® 
(escitalopram oxalate), and Depakote® (valproate sodium 
cocrystal with valproic acid).18 A particularly interesting recent 
result is the development of drug-drug cocrystals such as the 
1:1 cocrystal of tramadol and celecoxib.19 Amorphous 
materials and techniques used to study their local structure 
such as solid-state NMR spectroscopy18 and total scattering 
techniques20 have also seen considerable interest. The caveat 
is that amorphous materials are less thermodynamically stable 
than crystals and hence there is a need to find ways to stabilise 
them, particularly in the presence of moisture. In this context 
co-amorphous materials in the form of polymer blends with 
polymers such as polyvinylpyrrolidone are also increasingly 
common, but these have drawbacks such as the need for 
relatively large amounts of polymer. Small-molecule co-
amorphous21-23 materials including co-amorphous drug-drug 
preparations24 are beginning to be explored as a high solubility 
alternative. As a result of the popularity of co-crystalline and 
co-amorphous materials there has been considerable progress 
in the identification of suitable co-formers and methods used 
to screen for new co-crystalline and co-amorphous forms, Fig. 
3.25-30 
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Figure 3. Methods for co-crystal preparation (reproduced with permission from 
ref 18). 
 
 Another key area is the significant advances in the way in 
which new molecular solids are prepared and characterised. In 
2013 the Fujita group published an article in Nature entitled 
“X-ray analysis on the nanogram to microgram scale using 
porous complexes”.31 For the first time someone was 
proposing a solution to the age-old problem of compounds 
that are difficult to prepare as nice single crystals. Instead of 
trying to use artful techniques to induce the compound to 
crystallise by itself, the crystalline order is provided by pre-
grown crystals of coordination networks containing guest 
binding cages. The target compound is then introduced into 
the cages by allowing it to diffuse into the network of this 
‘crystalline sponge’. An ordered array of cages results in an 
ordered array of guest molecules suitable for single crystal 
diffraction, Fig. 4. While the method is not without its 
drawbacks such as low precision, and the need for the 
substrate to diffuse into the crystalline pores, it genuinely 
represents a step change in a very classical arena. 
 
Figure 4. Preparation of a guest included network complex: a single piece of 
crystalline sponge is treated for 2 d (possibly under sealed conditions for volatile 
liquids) with a drop of a liquid guest and subjected to X-ray data collection 
(reproduced with permission from reference 31). 
 
The crystalline sponge method is one of a host of recent, 
creative ways to prepare high quality crystals, new or different 
polymorphs and novel co-crystalline or amorphous forms. 
There are also recent developments in increasing throughput 
and control, influencing morphology or altering key properties 
such as dissolution rate, bioavailability, processability, stability 
and compressability.32 There has been considerable progress 
in the use of micro- or nanoconfinement for crystallization. 
Crystallization in microemulsion droplets has been shown to 
‘leapfrog Ostwald’s rule of stages’ and home in on the most 
thermodynamically stable solid form under a given set of 
conditions.33, 34 In addition to molecular compounds such as 
pharmaceuticals,35 the method has also been applied 
nanomaterials such as nanographite.36 Nanoscale confinement 
in materials such as porous polymers and nanoporous glass is 
also a powerful new crystallization tool.37 As Ward points out 
in a recent review: “nanoscale confinement examines 
nucleation and phase transformations at length scales 
corresponding to the critical size, at which kinetics and 
thermodynamics of nucleation and growth intersect and 
dramatic departures in stability compared to bulk crystals can 
appear”.38 Confined crystallization has been shown to result in 
novel outcomes under conditions of both ‘rigid confinement’ 
in materials such as silica39 and ‘soft confinement’ in 
polymers.40 In both cases, solid-state NMR spectroscopy is a 
useful in situ probe of crystallization outcome. Confined 
crystallization has also been used on patterned surfaces41, 42 
and in gel microparticles to give polymorph selective 
crystallization, particularly for the highly polymorphic (and 
difficult to control) olanzapine precursor ROY.43 Our own work 
has focussed on small molecule organogels to limit convection 
and provide an active surface for crystal nucleation. This 
includes gels specifically tailored to have chemical functionality 
mimicking the ubiquitous ROY. The gels have variable effects, 
sometimes favouring the most thermodynamically stable 
polymorph as in the crystals of Form III carbamazepine (Fig. 
5)44 and sometimes increasing nucleation rate of metastable 
polymorphs. Work in conjunction with gel structure calculation 
by Day suggests that an element of conformational biasing is 
involved with the observed selectivity.45 Related work by the 
Smith and Sanchez groups has shown that single46 and 
multicomponent gels involving dendrons and long chain 
aliphatic amines also results in effective pharmaceutical 
crystallization media.47 In addition, cationic surfactants in 
conjunction with nanocellulose have been used to gel-
crystallize a novel solvate of sulfapyridine, the drug credited 
with saving Winston Churchill’s life in 1943.48 
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Figure 5. Crystals of Form III carbamazepine growing in a supramolecular 
organogel (reproduced with permission from reference 44). 
 
   A particularly notable development reported by 
Cristóbal Viedma in 2005 involves the grinding of crystals 
suspended in solution as a means to deracemization and 
ultimately the production of enantiomerically pure solids 
induced by nonlinear autocatalysis and recycling, a technique 
known as Viedma ripening.49, 50 The technique has gained 
considerable prominence in the ensuing decade with recent 
work continuing to shed considerable mechanistic light on the 
role of abrasion and fracture of crystalline particles in attrition-
enhanced deracemization processes.51 
 As well as solution-mediated crystallization strategies, the 
21st century has seen an explosion in the application of 
mechanochemistry and liquid assisted grinding methods to the 
study of molecular solid form.52 While grinding often brings 
about amorphization, mechanochemistry can also proceed 
with recrystallization to give new polymorphs.53 It is also 
especially important in the discovery of novel co-crystals which 
may not form from solution, particularly in cases where the 
two components are of very different solubility.54 An 
interesting alternative is ‘vapour digestion’ – liquid assisted 
grinding without the grinding – in which exposure of pure 
components to solvent vapour results in co-crystal 
formation.55 
 Given the difficulty in obtaining single crystals for structural 
characterization from mechanochemical synthesis, creative 
techniques have evolved in order to study mechanochemical 
co-crystal formation such as terahertz time domain 
spectroscopy56 and milling apparatus compatible with in situ 
synchrotron X-ray diffraction.57 Rarer, non-mechanochemical 
solid-solid transformations have also become increasingly 
topical, particularly single-crystal-to-single-crystal 
transformations which can give mechanistic insight and also 
allow access to otherwise inaccessible polymorphs.58 In this 
context work by MacGillivray on topotactic transformations in 
co-crystals involving a template and photosensitive precursor 
can give rise to novel compounds such as ladderanes not 
readily accessible by conventional means.59 There was even a 
fascinating report in 2014 of a new form of ice, Ice XVI, 
generated by evacuation of neon from a structure II clathrate 
hydrate with retention of crystallinity.60 Ice XVI is the least 
dense pure solid form of water. 
 In conjunction with novel lab crystallization methods, there 
have also been significant advances in industrial techniques for 
preparing solid state materials and their application to co-
crystals in particular. These include particularly advances in 
continuous crystallization,61 milling,62 twin screw extrusion63 
and sonocrystallization.64  
 In addition to progress in the practical aspects of making 
crystals, there has also been a parallel growth in 
understanding the mechanism by which they form. For many 
years classical nucleation theory with its molecule-by-molecule 
growth of a critical sized nucleus was the dominant picture of 
crystal nucleation in most chemists minds.65 There has been an 
increasing appreciation of non-classical approaches, however. 
Two-step nucleation theory posits the evolution of a 
supersaturated system through a dense liquid phase that does 
not resemble the final crystal structure, followed by 
reorganisation of that dense aggregate cluster into an ordered 
structure (Fig. 6a).65 Non-classical mechanisms of crystal 
growth such as oriented attachment of smaller particles is also 
being increasingly recognised (Fig. 6b).66 Oriented attachment 
involves the spontaneous self-assembly of adjoining crystals 
with common crystallographic orientations and offers a 
powerful explanation of solid state chiral recognition 
phenomena.67  
(a)
 
(b) 
 
Figure 6. (a) Classical vs. non-classical nucleation models (reproduced with 
permission from reference 65) (b) Oriented attachment in gypsum crystals 
(reproduced with permission from reference 66)  
 
 The past decade has seen tremendous progress in 
computational crystal structure prediction (CSP) 
methodologies. A harbinger of change was the striking success 
of hybrid DFT methods in correctly calculating all four trial 
structures, including that of a co-crystal, in the 2007 
Cambridge blind tests.68 While subsequent blind tests have 
shown that many challenges remain, particularly with 
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conformationally flexible molecules and multicomponent 
systems,69 a hybrid DFT approach based on Monte Carlo 
parallel tempering for structure generation and final ranking 
with DFT predicted all five experimental structures in the 2016 
blind tests.70 Routine application of CSP remains limited by 
computational expense and the expertise needed to apply the 
methods. However, landmark work by the Price and Florence 
groups in 2011 resulted in the calculation of a new catermeric 
polymorph of the epilepsy medication carbamazepine, termed 
Form V. All of the previously known forms I-IV are based on 
hydrogen bonded dimers and hence the fact that the 
catemeric form V had not been experimentally observed 
despite its calculated stability must arise from the dominance 
of the dimers at the early nucleation stages. Price and Florence 
were able to overcome this barrier by experimentally growing 
the crystals of the predicted Form V on a template of the 
closely related dihydrocarbamazepine, Fig. 7. The approach is 
a general one and has very recently resulted in a new form of 
tolfenamic acid based on a computed prediction that identified 
a form of mefenamic acid as a suitable template.71 CSP 
approaches in combination with experimental TEM data also 
represent a powerful experimental approach to identification 
of new polymorphs present in tiny amounts, as in the case of a 
new form of theophylline present as a mixture with the well-
known Form II.72 
 The fact that CSP methods apparently ‘overpredict’ the 
number of possible stable forms is an ongoing puzzle.73 
However, wide-ranging exploration of the experimental space 
is beginning to show that some of these elusive calculated 
forms are real. In 2015 in silico polymorph screening revealed 
two potentially thermodynamically stable forms of the 
cardiovascular drug Dalcetrapib in addition to the known 
polymorphs.74 Subsequent investigation of the compound at 
high pressure allowed the experimental structure 
determination of one of the predicted forms. The 
experimental work showed that the new form is metastable at 
ambient pressure. The work effectively derisks the undesirable 
appearance of a more stable polymorph during late-stage 
development, as happened in the famous ritonavir case.75 
Similarly application of magnetic fields during coronene 
crystallization also revealed a novel, albeit not predicted, 
polymorph of this well-known compound.76 
 In addition to the major advances in computational CSP, 
there has also been a great deal of progress in ‘soft’ 
predictions in terms of the identification of trends in crystal 
engineering and their practical use in preparing designed solid 
forms. The importance of the Cambridge Structural Database, 
which is now approaching one million entries,77 is hard to 
overstate in this context. Some of the earliest systematic 
observational predictions were made back in 1990 by 
Margaret Etter in the form of Etter’s rules which focussed on 
hydrogen bonded systems in general and some specific 
systems such as nitroanilines, diaryl ureas, and some cocrystals 
in particular.78 In 1994 Brock and Dunitz made further 
systematic observations ‘towards a grammar of crystal 
packing’79 and in 1995 Desiraju published his powerful 
supramolecular synthon approach,80 which has been a 
substantial driver in a broad range of crystal engineering work 
ever since.81 Work by Aakeröy, for example, has shown that 
there is a hierarchy of supramolecular synthons that can be 
used to design multi-component cocrystals based on relative 
hydrogen bond acidity/basicity.82 There has also been growing 
interest in solid forms that do not conform to expected trends 
such as those with multiple molecules in the asymmetric unit 
(Z′ > 1).83, 84 Interestingly, while much work in crystal 
engineering has been concerned with the ability to design and 
control the ways in which molecules pack to give a crystal, 
work by Hosseini has also focussed on the macroscopic 
engineering of crystals themselves in a “crystal welding” 
approach involving the isomorphous deposition of closely 
related crystals of different metal complexes.85 
  
Figure 7. Crystals of the computationally predicted catemeric carbamazepine 
Form V  (I – iii) growing on a catermeric dihydrocarbamazepine form II seed 
crystal (reproduced with permission from ref. 86). 
 
 The past 20 years has also seen tremendous progress in 
molecular assembly in non-periodic structures. The field has 
been stimulated by the award of the 2011 Nobel Prize in 
chemistry to Shechtman for his work on quasicrystals.87 Within 
the field of molecular materials, developments on aperiodic 
ordered arrays of tetracarboxylic acid rhombus or Penrose 
tilings on surfaces have been enabled by the ability to directly 
image molecular arrays by STM.88, 89 
 The search for understanding of crystal structure has also 
led to intense scrutiny of the interactions the hold crystals 
together. Not just strong and directional interactions that are 
subject to facile design such as hydrogen bonds, but also 
weaker or less obvious interactions that have previously gone 
unrecognised. The past two decades has seen an explosive 
growth in the understanding of halogen bonding in 
particular,90 with halogen and hydrogen bonds acting as 
potentially mutually orthogonal supramolecular synthons.91 A 
number of other less well recognized supramolecular 
interactions such as anion- interactions,92, 93 chalcogen 
bonding,94 pnictogen bonding,95 and -hole interactions96 are 
also now being identified and finding application in crystal 
engineering. 
 The intense focus on the discovery and transformation of 
pharmaceutical solid forms in particular has led in some cases 
to the discovery of novel and unanticipated ways to bring 
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about solid-state phase transformations. Application of CO2 
gas pressure to the drugs clarithromycin and lansoprazole 
brings about facile conversion from unstable solvates to 
thermodynamically stable polymorphs.97 Despite the lack of 
the permanent pores that are associated with more rigid 
materials such as MOFs and zeolites, organic molecule solids 
have proven to be remarkably mobile and surprisingly 
permeable to fluid diffusion.98 As a result new applications for 
organic solids in gas storage and separation are being 
envisaged.99 A particular striking development in this context 
are the crystalline arrays of molecules with permanently 
engineered and predictable pores produced by the Cooper 
group.100 Remarkably this has also included liquids with 
permanent porosity.101 
 While of huge importance, the pharmaceutical sector has 
not been the only one to drive interest in organic solids. The 
solid state properties of agrochemicals and energetic materials 
are also of considerable interest and importance. As with 
pharmaceuticals, crystal engineering approaches and 
particular co-crystal formation can be used to modify or tune 
the behaviour of these substances. Work by the Aakeröy 
group, for example, has shown that co-crystallization 
approaches can be used to modulate the detonation 
properties of the energetic material ethylenedinitramine.102 In 
the agrochemicals sector co-crystal formation has been used 
to increase the melting point of the fungicides cyprodinil and 
dithianon.103 
 The 2016 Nobel Prize in chemistry has shone a spotlight 
onto the area of molecular machines.104-106 While much work 
on molecular machines is on isolated molecules either as a 
proof-of-principle in solution or confined on surfaces, 
crystalline arrays of molecular machines offer perhaps the 
most significant scope for a functional, high-density device. In 
this context work by the Garcia-Garibay group has focussed on 
what they term “amphidynamic crystals” including crystalline 
molecular motors and gyroscopes based on a wheel and axel 
type of approach.107 The growing control of crystal structure-
property relationships has also given rise to the ability of 
engineer functional crystals – a field termed “crystal 
adaptronics” which has given rise to systems such as 
mechanically reconfigurable elastic, superelastic and 
ferroelastic molecular crystals with properties such as bending 
and shape memory.108, 109 
 Finally, it is noteworthy that the contribution made by 
progress in instrumentation, particularly in X-ray 
crystallography has made the study of molecular solids, 
particularly under non-ambient conditions, increasingly 
accessible. The availability of high intensity sources such as the 
UK Diamond synchrotron with the I19 and I11 single crystal 
and high resolution powder diffraction beamlines110 makes 
structural characterisation of even marginal crystals and poorly 
crystallizing compounds such as gelators increasingly possible. 
Structure determination on tiny nanocrystals using electron 
diffraction applied to both biological samples111 and small 
molecules is also potentially revolutionary.112 Sample 
environments such as the very high pressures offered by the 
diamond anvil cell and high pressure gas cells, as well as ultra-
low temperature down to 2K are also making novel and 
dynamic structural experiments increasingly common.113 
Conclusions 
 The first decades of the 21st century have seen a quiet 
revolution in the understanding, prediction, control and 
importance of the organic and molecular solid state, rivalling 
that of ‘harder’ materials such as metal-organic frameworks. 
With the increasing molecular weight and hydrophobicity of 
recently discovered drugs, the optimization of solid state 
properties is becoming ever more important. Coupled with the 
intellectual property opportunities new solid forms can offer, 
formulation challenges are providing a strong industrial driver 
for the continued expansion in the exploration of molecular 
solid state chemistry. Understanding and control of molecular 
solids even in aperiodic and non-crystalline systems is 
experiencing dramatic advances as a result of techniques such 
as total scattering, high resolution microscopy, high intensity 
X-ray sources and electron diffraction. Control of molecular 3D 
packing offers scope for the realisation of arrays of functional 
molecular systems such as molecular machines and advanced 
properties such as controlled porosity, ferroelasticity and 
shape memory. The near future promises exciting progress in 
the determination of the structure of amorphous or 
nanocrystalline materials, the reliable and convenient 
prediction of all accessible crystal structures and in the 
understanding of the crystal nucleation process. 
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